Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis

and Market Forecasts to 2016

The Coronary Artery Disease Market is forecast to show Marginal Growth until 2016
The coronary artery disease (CAD) market is a highly competitive market and is expected
to become more competitive until 2016. Three major patent expiries are expected
during the forecast period, Plavix and Lipitor by 2011 and Crestor by 2016. The patient
expiries of these blockbuster drugs will trigger generic competition into the CAD market
making it more competitive. However, due to the increase in number of CAD patients
and the entry of novel therapies will be responsible for a stable growth between 2009
and 2016. The presently marketed products for the treatment of CAD have overall high
efficacy and safety standards. The market also has two other modes of treatment, which
are coronary artery bypass grafting (CABG) and angioplasty. The CAD mortality rate is
very high compared to other diseases due to coronary events associated with CAD,
including myocardial infarction (MI), angina and strokes. Therefore, the prevention of
such events still remains an untapped area of research and development for
pharmaceutical companies to bring novel drugs into the market. It would, therefore, be
sufficient for newer entrants to demonstrate a superior efficacy and safety profile in
order to capture value in the market from the currently used branded and generic
treatments.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Atherosclerosis-Or-Coronary-
Artery-Disease-CAD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData’s analysis estimates that Darapladib, Anacetrapib, Aliskiren and SCH 530348
are likely to get market approval as these drugs are expected to bring higher efficacy
and safety measures in the treatment of CAD. Some of these therapies are also likely to
bring changes in the treatment approach, by introducing much needed efficacy in the
reduction of the progression of atherosclerosis in CAD patients. These novel therapies
would remain market drivers in the future. Increases in the treatment seeking
population, prescription rates and the ageing global population are also considered to
be important drivers for this market. GlobalData’s analysis shows that the market grew
at a compound annual growth rate (CAGR) of 6.5% from $10.5 billion in 2001 to $17.4
billion in 2009. The market is predicted to grow at a marginal CAGR of 0.15% from 2009
and reach a total value of $17.6 billion by 2016. The marginal projected growth rate is
primarily attributed to the patent expiries of some of the major marketed products like
Lipitor, Crestor and Plavix. The availability of new first-in-class therapies with better
safety and efficacy profiles are expected to offset the negative impact of the patent
expiry of major drugs and drive the growth of the CAD market in the future.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Atherosclerosis-Or-Coronary-
Artery-Disease-CAD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Coronary Artery Disease Market is Set to Witness the Entry of Novel Class of
Therapeutic Product
GlobalData found the current competition in the CAD market to be strong as the market
is mainly governed by branded and generic products that have comparable safety and
efficacy profiles. This apart, major revenues for this market are generated by statins,
antiplatelet and anticoagulants, which are prescribed in addition to beta-blockers,
angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers
(ARBs), to achieve superior treatment in patients. The antiplatelet and renin inhibitors (a
new class of molecule) market is in itself set to witness a remarkable growth rate with
the approval of newer drugs. The entry of these newer classes of drugs will undoubtedly
accelerate the growth of the CAD market and also offset the negative impact of the
patent expiry of major products. This would, in turn, start a race for a new class of
pharmaceuticals with effective mechanisms of action. Merck & Co., Inc. is expected to
lead sales in the CAD market with the introduction of Anacetrapib and SCH 530348 in
the next few years. However, other products, such as Darapladib and Aliskiren, are also
likely to propel the growth of the market.

New Entrants Are Likely to Bring A Paradigm Shift from Treatment Options to
prevention of coronary events in Coronary Artery Disease
GlobalData found that that the presently available treatment options are successful in
meeting the market demand. Newer class of drugs like Aliskiren would bring much
needed efficacy in the reduction of the progression of atherosclerosis in CAD patients.
SCH 530348, an antiplatelet drug, is likely to reduce the risk of bleeding and improved
efficacy as compared to other antiplatelet products. Similarly, Darapladib, in a new class
of therapeutic agents, is a selective LpPLA2 inhibitor, and Anacetrapib is studied for the
long-term tolerability and efficacy in patients with CAD or other equivalent diseases.
Both are believed to present a more favorable risk-benefit ratio than the currently used
multi drug therapies. These may offer more comprehensive and effective methods to
tackle CAD. A paradigm shift is therefore predicted in this market.

GlobalData, the industry analysis specialist’s new report, “Atherosclerosis Or Coronary

Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016” is an
essential source of information and analysis on the global coronary artery disease (CAD)
market. The report identifies the key trends shaping and driving the market, and
provides insight into the prevalent competitive landscape and the emerging players
expected to bring a significant shift in the positioning of the existing market leaders.
Most importantly, the report provides valuable insight into the pipeline products within
the global CAD therapeutics sector.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Atherosclerosis-Or-Coronary-
Artery-Disease-CAD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or Visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782